Antibodies, diagnostics and research clarity
In multiplex immunoassays, the capture antibody receives most of the attention while the reporter antibody quietly determines signal quality, spectral compatibility and lot-to-lot reliability. This article sets out a practical selection and validation framework for UK laboratories that treat secondary reagents as measured components, not accessories.
Matrix changes are analytical changes, not administrative ones. This article sets out a UK-focused bridging dossier for antibody assays moving between serum, plasma, capillary blood and other specimen types, covering anticoagulant effects, haemolysis and lipaemia, collection variation and the evidence needed for a defensible sample-type claim.
When an immunoassay drifts, the antibody is often the first suspect and the last component that should be condemned. This formulation-first checklist helps UK laboratories separate buffer chemistry, blockers, stabilisers and conjugation effects from genuine antibody failure before reagent lots are written off.
Antibody interference can turn a routine immunoassay into a misleading result long before anyone questions the reagent lot. This practical guide examines rheumatoid factor, heterophile antibodies, HAMA and other sample-borne binding nuisances, and sets out a UK-focused checklist for detection, blocking and confirmation.
When an antibody supplier, expression system or conjugation process changes, the assay does not simply carry on. UK IVD developers need a structured bridging file that connects comparability data to assay performance and UKCA evidence. This checklist sets out what a defensible handover should contain in 2026.
Datasheet dilutions are a starting point, not an SOP. In UK laboratories, matrix effects, lot drift and automated platforms make local titration a governance issue as much as a technical one. This opinion piece sets out a pragmatic 2026 framework for treating dilution as evidence to be generated, not instruction to be copied.
UKCA marking is not a single hurdle but a sequence of evidence, registration and labelling decisions. This guide sets out where CE marking still carries weight in Great Britain, the documentation points that most often stall small diagnostic developers, and a practical checklist for planning submissions in 2026.
Antibody laboratories generate valuable knowledge about validation, lot history and troubleshooting, but much of it disappears when fixed-term researchers move on. A lightweight documentation culture and a shared antibody registry can keep that hard-won experience inside the laboratory.
Antibody performance is often treated as a property of the vial, but it is also a property of the conditions under which the vial is kept. This article sets out a proportionate storage audit for UK laboratories—covering temperature records, freeze–thaw history, glycerol concentration and freezer resilience—that can stand up to grant review, quality scrutiny and supplier discussion.
Affinity constants are useful shorthand, but they do not describe how an antibody will behave in a bivalent assay, in a complex sample matrix or after immobilisation on a plastic surface. UK diagnostic developers need a selection framework that treats avidity, format and interference as first-class variables.
Antibody reagent supply is no longer a procurement afterthought for UK laboratories. This contingency map sets out how research and diagnostic teams can reduce customs friction, cold-chain delays and single-source vendor risk in 2026.
UK diagnostic developers are taking a fresh look at polyclonal antibodies for lateral flow, not as a legacy ascites product but as a practical option for complex matrices and supply resilience. This review sets out the technical and regulatory criteria that should guide selection in 2026.
Antibody validation is still too often treated as a final checkbox rather than a design requirement. This opinion piece offers a practical audit for UK laboratories and explains how to build knockout or knockdown evidence into grant applications without inflating the budget.
Recombinant antibodies are no longer a niche alternative, but the shift from hybridoma-derived reagents is not automatic. This analysis examines what the change means for UK startups, NHS diagnostic suppliers and academic core facilities, and sets out the commercial, IP and regulatory questions that should be asked early.